Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

This study provides a valuable look at genome-wide RNaseA-resistant RNA-DNA interactions in human embryonic stem cells. The research indicated that RNase treatment maintained long-range RNA-chromatin ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

In all living organisms, DNA contains the code that defines cellular structures and functions. An enzyme called RNA ...

Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with ...

We can already tinker with human DNA to treat diseases. But being able to edit RNA allows for even more precision – and fewer ...

This research report explores the global RNA sequencing market, providing an analysis of its trends and projections through 2029. It breaks down the market by product, technology, application, end ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.